Literature DB >> 6865907

A portion of [3H]cocaine binding in brain is associated with serotonergic neurons.

M E Reith, H Sershen, D L Allen, A Lajtha.   

Abstract

Three lines of evidence are brought forward in support of an association in the brain cortex of some, but not all, of the cocaine binding sites with serotonergic nerve terminals. The first is based upon the significant correlation observed between the inhibition of cocaine binding by various drugs and the inhibition of neuronal uptake of serotonin in the mouse cerebral cortex. The second is based upon the demonstration of cocaine binding in human blood platelets, a model system for central serotonergic neurons. The third comes from experiments in which rats were treated with p-chloroamphetamine and 5,7-dihydroxytryptamine (serotonin neurotoxins), 6-hydroxydopamine (catecholamine neurotoxin), or p-chlorophenylalanine (inhibitor of tryptophan hydroxylase). Only the serotonin neurotoxins decreased the binding of [3H]cocaine in the rat cerebral cortex, but to a lower extent than the binding of [3]imipramine, which is known to be associated with serotonergic terminals. In contrast to the cocaine binding in the mouse cerebral cortex, the binding in the rat cerebral cortex included a considerable portion of low-affinity binding that was relatively unaffected by lesions of serotonergic neurons.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6865907

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  13 in total

1.  Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects.

Authors:  N D Volkow; G J Wang; S J Gatley; J S Fowler; Y S Ding; J Logan; R Hitzemann; B Angrist; J Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

2.  Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats.

Authors:  Patrick M Beardsley; James L Howard; Keith L Shelton; F Ivy Carroll
Journal:  Psychopharmacology (Berl)       Date:  2005-10-22       Impact factor: 4.530

Review 3.  Single-photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson's disease.

Authors:  R B Innis
Journal:  Eur J Nucl Med       Date:  1994-01

4.  Modification of behavioral effects of cocaine by selective serotonin and dopamine uptake inhibitors in squirrel monkeys.

Authors:  R D Spealman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Cocaine binding sites in fetal rat brain: implications for prenatal cocaine action.

Authors:  J S Meyer; L P Shearman; L M Collins; R L Maguire
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Inhibitory synaptic potentials recorded from mammalian neurones prolonged by blockade of noradrenaline uptake.

Authors:  A Surprenant; J T Williams
Journal:  J Physiol       Date:  1987-01       Impact factor: 5.182

7.  Binding of imipramine and cocaine to a model lipid membrane: comparison with binding to brain membranes.

Authors:  M E Reith; H Sershen; A Lajtha
Journal:  Neurochem Res       Date:  1984-07       Impact factor: 3.996

8.  [3H] cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: allosteric modulation by paroxetine.

Authors:  H C Akunne; B R de Costa; A E Jacobson; K C Rice; R B Rothman
Journal:  Neurochem Res       Date:  1992-12       Impact factor: 3.996

9.  Serotonin (2C) receptor regulation of cocaine-induced conditioned place preference and locomotor sensitization.

Authors:  Caryne P Craige; Ellen M Unterwald
Journal:  Behav Brain Res       Date:  2012-10-26       Impact factor: 3.332

10.  Spermine interacts with cocaine binding sites on dopamine transporters.

Authors:  M C Ritz; C R Mantione; E D London
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.